

Expansion of existing and creation of new facilities in Central Government Hospitals are on-going process and are undertaken as per requirement and availability of resources. In such pursuit, the Government has under-taken extensive development plan including increase in the bed strength in respect of these Central Government Hospitals/Institutes.

### **Dengue cases**

445. SHRI T.K. RANGARAJAN: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) the number of persons affected by Dengue fever in the last three years, Statewise;
- (b) the number of deaths due to Dengue fever in the last three years, State-wise;
- (c) whether any vaccine has been discovered as prophylactic; and
- (d) whether any research has been undertaken by any institution in that direction?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI ASHWINI KUMAR CHOUBEY): (a) and (b) As per the reports submitted by States/ UTs Dengue cases and deaths reported during last 3 years and in 2017 (till 30th November) are as under:

Year	2014	2015	2016	2017 (till 30th Nov.)
Cases	40571	99913	129166	150482
Deaths	137	220	245	225

Details of state-wise Dengue cases and deaths reported during the last three years and the current year (till November, 2017) in the country are given in the Statement (*See below*).

(c) and (d) As per the information received from Indian Council of Medical Research (ICMR), Delhi, till date there is only one dengue vaccine which is marketed - Dengvaxia from Sanofi Pasteur.

Details of Dengvaxia as well as other dengue vaccines/ candidates are as follows:

Global dengue vaccines/candidates:

1. CYD-TDV or Dengvaxia of Sanofi Pasteur: This live attenuated vaccine is made of non-structural proteins of YF17D. It is recommended in 3 doses

0/6/12 months at 9+ years of age. This vaccine is marketed in more than 18 countries now.

2. TDV (Takeda): This live attenuated vaccine is made from non-structural proteins of DENV2. It is recommended in 2 doses 0/3 months between 4-16 years of age. This vaccine will enter Phase III clinical trials in 2018.
3. TV003/TV005 (NIH & InstitutoBhutantan): This live attenuated vaccine is made from non-structural proteins of DENV 1/3/4. It is recommended as 1 dose between 2-59 years of age. This vaccine will enter Phase III clinical trials in 2018.

Indian Dengue vaccine candidates:

4. Panacea Dengue Vaccine: This is a cell culture derived live attenuated, recombinant, freeze dried, lyophilized tetravalent vaccine with seed strain borrowed from National Institute of Health (NIH), USA. The Company has successfully completed Pre-clinical toxicology studies. Drug Controller General India DCG(I) has granted permission to conduct clinical Phase I/II studies.
5. Serum Institute of India: This is also cell culture derived live attenuated, recombinant, freeze dried, lyophilized tetravalent vaccine with seed strain borrowed from National Institute of Health (NIH), USA. Preclinical toxicity study will be initiated soon.

International Centre for Genetic Biotechnology (ICGEB)-Sun Pharma collaborative vaccine (DSV4): This is a recombinant vaccine on Virus - Like Particles (VLP) platform. It is a-tetravalent four-in-one Virus - Like Particles(VLP) design, expressed in Yeast vaccine which elicits antibodies to all four DENV serotypes in a shorter schedule of 0,1 and 2 months. Expected to initiate Phase I clinical trials by 2020.

#### Statement

##### *Details of State-wise Dengue cases and deaths in the country*

Sl. No.	State	2014		2015		2016		2017 (Prov till 30th Nov.)	
		Cases	Deaths	Cases	Deaths	Cases	Deaths	Cases	Deaths
1	2	3	4	5	6	7	8	9	10
1.	Andhra Pradesh	1262	5	3159	2	3417	2	4381	0

1	2	3	4	5	6	7	8	9	10
2.	Arunachal Pradesh	27	0	1933	1	13	0	15	0
3.	Assam	85	0	1076	1	6157	4	4346	2
4.	Bihar	297	0	1771	0	1912	0	1804	0
5.	Chhattisgarh	440	9	384	1	356	0	388	0
6.	Goa	168	1	293	0	150	0	234	0
7.	Gujarat	2320	3	5590	9	8028	14	4420	4
8.	Haryana	214	2	9921	13	2493	0	4333	1
9.	Himachal Pradesh	2	0	19	1	322	0	442	0
10.	Jammu and Kashmir	1	0	153	0	79	1	403	0
11.	Jharkhand	36	0	102	0	414	1	689	5
12.	Karnataka	3358	2	5077	9	6083	8	16342	5
13.	Kerala	2575	11	4075	25	7439	13	19694	36
14.	Madhya Pradesh	2131	13	2108	8	3150	12	2566	6
15.	Meghalaya	0	0	13	0	172	0	40	0
16.	Maharashtra	8573	54	4936	23	6792	33	6894	34
17.	Manipur	0	0	52	0	51	1	187	1
18.	Mizoram	19	0	43	0	580	0	107	0
19.	Nagaland	0	0	21	1	142	0	191	0
20.	Odisha	6433	9	2450	2	8380	11	4055	6
21.	Punjab	472	8	14128	18	10439	15	15002	0
22.	Rajasthan	1243	7	4043	7	5292	16	7768	16
23.	Sikkim	5	0	21	0	82	0	659	0
24.	Tamil Nadu	2804	3	4535	12	2531	5	21350	52
25.	Tripura	6	0	40	0	102	0	103	0
26.	Telangana	704	1	1831	2	4037	4	2773	0

1	2	3	4	5	6	7	8	9	10
27.	Uttar Pradesh	200	0	2892	9	15033	42	3032	28
28.	Uttarakhand	106	0	1655	1	2146	4	958	0
29.	West Bengal	3934	4	8516	14	22865*	45	10697**	19
30.	Andaman and Nicobar Island	139	0	153	0	92	0	13	0
31.	Chandigarh	13	0	966	1	1246	0	1083	0
32.	Delhi	995	3	15867	60	4431	10	8896	4
33.	Dadra and Nagar Haveli	641	1	1154	0	4161	2	1972	0
34.	Daman and Diu	46	0	165	0	89	0	59	0
35.	Puducherry	1322	1	771	0	490	2	4586	6
TOTAL		40571	137	99913	220	129166	245	150482	225

\* During 2016, the State of West Bengal submitted report till 9th November only.

\*\* During 2017, the State of West Bengal submitted report till 4th October only.

### Combating vector-borne diseases

446. SHRIMATI AMBIKA SONI:

DR. T. SUBBARAMI REDDY:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) the amount released for combating vector-borne diseases in the last three years, year-wise;

(b) how much of the funds had been utilized during the period, year-wise;

(c) whether there is rise in the number of dengue and chikungunya cases in the country, if so, whether Government has introduced any strategic plan to deal with it, State-wise details thereof; and

(d) whether there is any specific plan to monitor and combat the situation, especially in the worst-affected areas in various States, if so, the details thereof?